Clinical Trial

A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy

Study acronym: 8212-Preserved
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study will look into how CDR132L (a potential new medicine) works on the structure and function of the heart in people living with heart failure. Participants will either get CDR132L or placebo (a medicine which has no effect on the body), which treatment the participants get is decided by chance. The study will last for about 60 weeks.
Protocol Amendment History 3 changes
notable Trial sites expanded: 109 -> 115 locations 2026-07-10
notable Primary completion pushed: 2027-05-16 -> 2027-11-16 2026-07-10
minor Completion pushed: 2028-01-23 -> 2028-07-25 2026-07-10
Trial Details
NCT Number NCT06979362
Lead Sponsor Novo Nordisk A/S
Conditions Heart Failure
Enrollment 200 participants
Start Date 2025-06-27
Primary Completion 2027-11-16 (estimated)
Study Completion 2028-07-25 (estimated)
Updated on ClinicalTrials.gov 2026-07-09